Invasive pneumococcal infections and the impact of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13). 2021 Report.

Key Points

  • In 2021, the overall incidence rate of invasive pneumococcal infections decreased, but the decline was less pronounced than in the previous year and varied by age group.

  • The incidence rate was highest and rising again among children under 2 years of age, though levels remained below those of 2019, before the onset of the COVID-19 pandemic.

  • Among those aged 65 and older, incidence rates remain among the highest, with a more moderate decrease compared to the previous year.

  • The majority of infections were caused by serotypes not included in the PCV13 vaccine (notably serotype 8 in adults and serotype 24F in children), as well as by serotype 3 (included in PCV13) in adults.

In relation to

Our latest news

news

“Protecting the Public from the Risks of Alcohol.” The special report in *La...

news

Call for Applications to Fill Vacancies on the National Committee on...

news

Sexual Health Week 2026: Screening and Prevention Remain Essential